Filing Overview
Company named in filing: Eliem Therapeutics, Inc. The request metadata identifies Climb Bio, Inc., but the filing text identifies Eliem Therapeutics. This Form 8-K was filed March 16, 2023, reporting events effective March 10, 2023.
Business Context and Reporting Period
The filing reports executive officer changes under Item 5.02. It does not present quarterly or annual financial results and does not cover a financial reporting period.
Management Changes
- Erin Lavelle mutually agreed to resign as Executive Vice President, Chief Operating Officer and Chief Financial Officer.
- Effective March 10, 2023, the Board appointed Andrew Levin, Executive Chairman, as principal financial officer in addition to principal executive officer.
- Emily Pimblett, Chief Accounting Officer, was appointed principal accounting officer.
- Levin is a co-founder and former CEO of Eliem and has served as Chairman since February 2019 and Executive Chairman since February 2023.
- Pimblett has served as Vice President of Accounting since March 2021 and Chief Accounting Officer since February 2023. She is a licensed CPA in Washington.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balance, liquidity, guidance or other financial metrics.
Material Changes, Related-Party Matters and Risks
- The filing discloses that Eliem is party to an investor rights agreement with certain stockholders, including entities affiliated with Levin.
- A prior services agreement with Carnot, LLC and successor agreements was terminated on December 2, 2022. Carnot Pharma provided drug-discovery, research and development services, for which Eliem paid based on personnel time.
- RA Capital Management, L.P. manages the members of Carnot Pharma, and Levin is President of Carnot Pharma, creating a disclosed related-party connection.
- The filing states that Levin has a direct or indirect material interest in certain company transactions exceeding $120,000. No transaction amounts are provided in the filing text.
- The filing states that neither Levin nor Pimblett has a family relationship with any director or executive officer. Pimblett was not party to a transaction requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Priorities
- Verify the issuer identity, because the filing names Eliem Therapeutics rather than Climb Bio.
- Review subsequent filings for the impact of Lavelle’s departure and the concentration of principal executive and financial officer responsibilities with Levin.
- Review the investor rights agreement and related-party disclosures involving Levin, RA Capital and Carnot Pharma.
- Confirm whether later filings provide financial results, cash runway, financing plans or additional executive compensation details.